News | August 06, 2008

New Sternal Closure Device Reported Provides Improved Stability and Reduced Pain for Heart Patients

August 7, 2008 - KLS Martin LP, a medical device company specializing in craniomaxillofacial and sternal fixation, yesterday announced the implantation of the Sternal Talon in the 500th patient.

The Sternal Talon is an alternative method of closure for midline sternotomies used in many heart procedures and utilizes rigid orthopedic-style fixation. Originally developed in conjunction with surgeons at Duke University and surgeons in Tulsa, OK, as a reconstructive alternative for patients with sternal instability and non-unions, the Sternal Talon has been used successfully in primary closure for patients undergoing midline sternotomy for CABG (coronary artery bypass graft) and valvular surgery. Many of these 500 patients had multiple comorbidities, which often lead to significant infections that can be fatal. These patients represent a truly difficult population for sternal closure and until recently the cardiothoracic surgeon had very few treatment options.

“The most common method of sternal closure remains sternal wire, but this is not without problems, especially in the larger patients,” said Dr. Arch Miller, one of the inventors from Tulsa, OK. “The patients often exert forces on the wires that can cause the wires to break, pull through the bone or loosen which can lead to sternal instability, infection and increased pain.”

Using the Sternal Talon on patients with higher BMI (body mass index) improves the chances for better fixation, potentially reducing the risk of sternal complications and resulting in lower patient pain scores allowing them faster recovery, the company said.

Currently, KLS Martin Sternal Talons are available in a select group of heart hospitals in the U.S. The initial experience and feedback from doctors, nursing staff and patients is very positive, the company said.

A multi-center study to evaluate the outcomes of similar high-risk patients with standard wire closure compared to the Sternal Talon is underway with the team at Duke University Medical Center and results should be available in the next 18 months. The study at Duke is being led by physicians other than those who were involved in the initial development of the Sternal Talon.

For more information: www.klsmartin.com, www.rapidsternalclosure.com


Related Content

News | Cardiovascular Surgery

April 23, 2024 — Medtronic plc, a global leader in healthcare technology, today announced the launch of its latest ...

Home April 23, 2024
Home
News | Cardiovascular Surgery

March 20, 2024 — PECA Labs, a medical device company reimagining the field of vascular grafts and valves with durable ...

Home March 20, 2024
Home
News | Cardiovascular Surgery

February 26, 2024 — Hackensack Meridian Jersey Shore University Medical Center and Hackensack University Medical Center ...

Home February 26, 2024
Home
Feature | Cardiovascular Surgery

The DAIC team has learned of the passing of Alain Cribier, MD, FACC, heralded as the man who pioneered the first ...

Home February 23, 2024
Home
News | Cardiovascular Surgery

January 29, 2024 — Despite national guidelines recommending surgical aortic valve replacement (SAVR) for patients under ...

Home January 29, 2024
Home
News | Cardiovascular Surgery

January 11, 2024 — Paragonix Technologies, a pioneer in organ transplant solutions, is proud to announce the publication ...

Home January 11, 2024
Home
News | Cardiovascular Surgery

December 20, 2023 — The Smidt Heart Institute at Cedars-Sinai has opened an Aortic Surveillance Clinic for the ...

Home December 20, 2023
Home
News | Cardiovascular Surgery

December 18, 2023 — The Department of Cardiovascular Surgery at The Mount Sinai Hospital has received the highest ...

Home December 18, 2023
Home
News | Cardiovascular Surgery

November 2, 2023 — The University of Maryland Medical Center (UMMC) released a statement on the passing of a patient ...

Home November 02, 2023
Home
News | Cardiovascular Surgery

October 25, 2023 — Edwards Lifesciences announced new data from the PARTNER 3 trial demonstrating continued low rates of ...

Home October 25, 2023
Home
Subscribe Now